Somatotropin or growth hormone is a substance that is actively involved in the growth and development of muscle and bone tissue. No wonder it has become so popular in sports and is now part of the sports pharmaceutical industry. In some cases its use is preferable to the use of steroids, as Hygetropin 10 IU Zhongshan has virtually no side effects.
Hygetropin 10 IU Zhongshan – Hygene Biopharm Co. is manufactured in China and is a recombinant growth hormone.
Main positive properties of Hygetropin 10 IU Zhongshan
Hygetropin 10 IU Zhongshan cannot be called a universal substance for all sports purposes. Above all, it is used in bodybuilding, as it modifies the figure and does not affect the athlete’s performance.
- promotes a set of high-quality muscle mass;
- burns subcutaneous fat and promotes weight loss;
- strengthens bone tissue, reduces the risk of injury;
- accelerates regeneration, helps to recover.
The drug increases the amount of insulin-like growth factor. This is due to the anabolic and anti-catabolic effects of the hormone.
In addition, Hygetropin 10 IU Zhongshan rejuvenates the body, has a beneficial effect on the condition of the skin and nails. It is used by female athletes to make the figure more expressive, the relief sharper and the skin look younger.
The muscles recruited in the course are of high quality: dryness, stiffness, venous tightness and pronounced definition. There is no reversal phenomenon. The hormone affects the growth of connective tissues, so it is suitable for people with problems in this area.
Possible side effects
In most cases, the course of Hygetropin 10 IU Zhongshan passes without side effects. But with increased sensitivity of the body to the component, high doses and long-term use, negative manifestations may occur. For example:
- tunnel syndrome, when the nerve is pinched by the surrounding tissues;
- high blood pressure;
- swelling due to excessive accumulation of fluid in the cells;
- decreased activity of the thyroid gland.
It also increases the blood sugar level, which may be a problem for some people. Before using the medicine, you should consult a doctor.
Dosage and intake rules
Hygetropin 10 IU Zhongshan should be taken daily. The duration of the course depends on the athlete’s goals and how quickly the effects of the drug appear. Generally, the duration of the course is 6 weeks.
The drug does not increase strength and endurance. On the contrary, it can reduce them and cause faster fatigue. Given this, you should inject the drug at the right time. For example, before going to bed. The intake plan can also be constructed individually, taking into account your training schedule, meals and activities.
Before using other anabolics in conjunction with this drug, consult and find out if there are any contraindications.
List of references
- Ranke MB, Lindberg A. Observed and predicted growth responses in prepubertal children with growth disorders: guidance of growth hormone treatment by empirical variables. J Clin Endocrinol Metab. 2016;101(4):1383-1390. doi: 10.1210/jc.2015-4069
- Johannsson G, Bidlingmaier M, Biller BMK, et al. Growth Hormone Research Society perspective on biomarkers of GH action in children and adults. Endocr Rev. 2018;39(5):1-46. doi: 10.1210/er.2018-00003
- Grimberg A, DiVall SA, Polychronakos C, Allen DB, Cohen LE, Quintos JB, Rossi WC, Feudtner C, Murad MH, Drug and Therapeutics Committee and Ethics Committee of the Pediatric Endocrine Society. Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. Horm Res Paediatr. 2016;86(6):361-397. doi: 10.1159/000452150
- Desai SS, Savani RC. Nanotechnology: a review of nanotubes in cancer detection and therapy. J Nanomed Nanotechnol. 2011;2(3):116. doi: 10.4172/2157-7439.1000116
- Scheepens A, Sijben JW, Nieuwenhuizen AG. The metabolic and endocrine response to nutritional intervention with a special amino acid mixture in patients after gastrointestinal surgery. Nutr Hosp. 2005;20(5):325-332